Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF® Development Program

Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the
                        AEROSURF® Development Program

PR Newswire

WARRINGTON, Pa., Oct. 8, 2013

WARRINGTON, Pa., Oct. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc.
(NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new
standard of respiratory critical care, today announced that the United States
Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a
patent entitled "Capillary System With Fluidic Element." The Company holds a
license to this patent (U.S. Patent Application. No. 12/285,312), which will
provide additional exclusivity regarding certain proprietary and technical
aspects of its capillary aerosol generator (CAG) technology, a key component
of its AEROSURF^® program.

Discovery Labs' technology platform includes its synthetic, peptide-containing
KL4 surfactant and its proprietary aerosolized drug delivery technologies,
including the CAG technology, which has the potential to enable delivery of
aerosolized KL4 surfactant without the invasive procedures currently required
for surfactant administration. Discovery Labs previously secured worldwide
exclusive rights to the CAG technology for use with all pulmonary surfactants,
alone or in combination with other pharmaceutical compounds, for a wide range
of respiratory disorders. The initial application of the CAG technology is
for the Company's AEROSURF development program.

AEROSURF is a novel investigational combination drug-device product being
developed to deliver Discovery Labs' KL4 surfactant in aerosolized form to
premature infants with respiratory distress syndrome (RDS). AEROSURF could
potentially allow for the administration of KL4 surfactant to premature
infants without invasive endotracheal intubation, and may enable the treatment
of a significantly greater number of premature infants who could benefit from
surfactant therapy but are currently not treated. The Company plans to
initiate its AEROSURF phase 2 clinical program in the fourth quarter of 2013.

"We are pursuing a broad exclusivities strategy and this patent further
enhances a growing list of potential regulatory and patent related
exclusivities and provides additional protections for our valuable AEROSURF
program," said John G. Cooper, Chief Executive Officer of Discovery Labs.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care. Discovery Labs'
technology platform includes its novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally similar to
pulmonary surfactant, and its proprietary drug delivery technologies being
developed to enable efficient delivery of aerosolized KL4 surfactant and other
inhaled therapies. Discovery Labs' strategy is initially focused on
neonatology and improving the management of respiratory distress syndrome
(RDS) in premature infants. Discovery Labs believes that its RDS product
portfolio has the potential to become the new standard of care for RDS and,
over time, enable the treatment of a significantly greater number of premature
infants who could benefit from surfactant therapy but are currently not
treated.

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties, including those
related to Discovery Labs' efforts to secure exclusivity protections for its
drug and medical device products through patents, are described in Discovery
Labs' filings with the Securities and Exchange Commission, including the most
recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any
forward-looking statement in this release speaks only as of the date on which
it is made. Discovery Labs assumes no obligation to update or revise any
forward-looking statements.

SOURCE Discovery Laboratories, Inc.

Website: http://www.discoverylabs.com
Contact: Company, John Tattory, Vice President, Finance: 215.488.9418 or
jtattory@discoverylabs.com or Investor Relations, Michael Rice, LifeSci
Advisors: 646.597.6979 or mrice@lifesciadvisors.com or Media Relations,
Michael Parks, Pitch360: 484.356.7105 or Michael@pitch360inc.com
 
Press spacebar to pause and continue. Press esc to stop.